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ttp://dx.doi.org/10.1016/j.jmoldx.2013.10.005Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in PKD1 and PKD2.
However, genetic analysis is complicated by six PKD1 pseudogenes, large gene sizes, and allelic het-
erogeneity. We developed a new clinical assay for PKD gene analysis using paired-end next-generation
sequencing (NGS) by multiplexing individually bar-coded long-range PCR libraries and analyzing them in
one Illumina MiSeq ﬂow cell. The data analysis pipeline has been optimized and automated with Unix shell
scripts to accommodate variant calls. This approach was validated using a cohort of 25 patients with
ADPKD previously analyzed by Sanger sequencing. A total of 250 genetic variants were identiﬁed by NGS,
spanning the entire exonic and adjacent intronic regions of PKD1 and PKD2, including all 16 pathogenic
mutations. In addition, we identiﬁed three novel mutations in a mutation-negative cohort of 24 patients
with ADPKD previously analyzed by Sanger sequencing. This NGS method achieved sensitivity of 99.2%
(95% CI, 96.8%e99.9%) and speciﬁcity of 99.9% (95% CI, 99.7%e100.0%), with cost and turnaround
time reduced by as much as 70%. Prospective NGS analysis of 25 patients with ADPKD demonstrated a
detection rate comparable with Sanger standards. In conclusion, the NGS method was superior to Sanger
sequencing for detecting PKD gene mutations, achieving high sensitivity and improved gene coverage.
These characteristics suggest that NGS would be an appropriate new standard for clinical genetic testing
of ADPKD. (J Mol Diagn 2014, 16: 216e228; http://dx.doi.org/10.1016/j.jmoldx.2013.10.005)Supported by The Rockefeller University Center for Clinical Trans-
lational Science (J.B.), National Center for Research Resources/NIH grant
UL1 RR024143-01 (J.B.), the NIH Roadmap for Medical Research (J.B.),
and by the Starr Foundation (J.B.).
Disclosures: None declared.Autosomal dominant polycystic kidney disease (ADPKD) af-
fects 1 in 400 to 1 in 1000 live births worldwide.1 It is the most
common inherited kidney disease, accounting for approxi-
mately 5% of the end-stage renal disease population.2 ADPKD
is initiated by gene mutations in renal tubular epithelial cells,
which seem to be more sensitive to haploinsufﬁciency, result-
ing in increased proliferation and cyst formation.3 The conse-
quent increase in the number and size of kidney cysts causes
progressive chronic kidney disease.4 ADPKD is mainly caused
by mutations in two large genes, PKD1 and PKD2, accounting
for 75% to 85% and 15% to 25% of cases, respectively, instigative Pathology
.clinically well-characterized populations. PKD1 spans 46
exons and encodes polycystin-1 with 4303 amino acids.5
PKD2 spans 15 exons, encoding polycystin-2, which consists
of 968 amino acids.6 Chromosome 16 includes six homologous
genes (ie, pseudogenes) that share 97.7% sequence identity
with the PKD1 gene exons 1 to 33.7,8
ADPKD Mutation Analysis by NGSThe clinical diagnosis of ADPKD is established by family
history and renal imaging modalities, such as ultrasonogra-
phy, computed tomography, and magnetic resonance imag-
ing.9 However, these diagnostic test results are often
ambiguous, particularly in young individuals. Consequently,
genetic testing plays an increasingly important role in the
diagnosis and management of patients with ADPKD.10
Moreover, with the development of potentially effective
pharmacologic treatments for ADPKD,11 the need for accu-
rate diagnostic genetic tests has become more compelling.
The key step in ADPKD genotyping procedures is ampliﬁ-
cation of the PKD1 gene region while excluding the pseudo-
genes. Thiswas traditionally achieved by using long-range PCR
(LR-PCR) with primers located to the rare mismatch sites that
distinguish PKD1 and the pseudogenes, followed by nested
PCRof the individual exons, whereas the single-copy regions of
PKD1 and PKD2 were directly ampliﬁed from genomic DNA.
Ampliconswere then directly analyzed bySanger sequencing or
by sequencing coupled with a mutation screening step to lower
the testing cost.12,13However, the genetic analysis ofADPKD is
challenging, especially owing to the large size, complex
genomic structure, and allelic heterogeneity of PKD1 and
PKD2.14 Next-generation sequencing (NGS) technology has
revolutionized the ﬁeld of human genetics and molecular di-
agnostics.15,16 Recently, Rossetti et al17 reported a mutation
screening strategy for analyzing PKD genes using NGS by
pooling LR-PCR amplicons and multiplexing bar-coded li-
braries. This approach was designed to have a high throughput
and has been successful for screeningmutations in large cohorts.
However, the method had low sensitivity and slow turnaround
time, mainly because of the sample pooling strategy used.
Herein, we present a new NGS-based genotyping
approach for patients with ADPKD that is better tailored to
the standard clinical diagnostic setting, where rapid turn-
around time and high sensitivity could be achieved by
individually bar coding each patient in the run. The diag-
nostic performance of the new assay was evaluated using a
panel of DNA samples previously analyzed by Sanger
sequencing.18 The testing strategy, workﬂow, data analysis
pipeline, costs, and other related issues are also discussed.
Materials and Methods
Study Patients
Study patients were participants in The Rogosin Institute
Polycystic Kidney Disease Data Repository (http://www.
clinicaltrials.gov, Identiﬁer NCT00792155). This is a single-
center, prospective, longitudinal study of genotype and pheno-
type characteristics of individuals with ADPKD. Study samples
were randomly selected for analysis. All the participants un-
derwent PKDgenotyping by theWeill CornellMedical College
Molecular Pathology Research Laboratory (New York, NY)
using direct sequencing or SURVEYOR nucleaseeWAVE
screening (Transgenomic Inc., Omaha, NE). In addition, we
prospectively analyzed a new cohort of patients with ADPKDThe Journal of Molecular Diagnostics - jmd.amjpathol.orgthat has not beenpreviouslygenotyped.The studywasapproved
by the Institutional Review Board Committees at Weill Cornell
Medical College and The Rockefeller University (New York,
NY). All the participants provided written informed consent.
Long-Range PCR
Genomic DNA was extracted from peripheral blood lympho-
cytes using a Gentra Puregene blood kit (Qiagen Inc., Valencia,
CA). The entire coding region, the exon-intron boundaries, and
most of the 50 and 30 untranslated regions of PKD1 and PKD2
were ampliﬁed in a total of 10 (ﬁve reactions per gene) distinct
PCR reactions using primers anchored either in the rare mis-
matched regionwith the human homologs or in the single-copy
region of PKD1. The LR-PCR primers were designed using
Primer3 software version 4.0.0 (http://bioinfo.ut.ee/primer3,
last accessed October 25, 2013) (Table 1).19 The LR-PCR
primers were modiﬁed at the 50 end with NH2 to prevent
overrepresentation of sequences at the amplicon ends in the
ligation step and to increase sequence coverage uniformity.20
LR-PCR was performed using either the GeneAmp high ﬁ-
delity PCR system (Applied Biosystems, Foster City, CA) or
the PrimeSTAR GXL DNA polymerase (Takara Bio Inc.,
Shiga, Japan). PCR ampliﬁcation conditions for the various
LR-PCR fragments are described in Supplemental Table S1.
After puriﬁcation with Agencourt AMPure XP beads (Beck-
man Coulter, Beverly, MA), the LR-PCR fragments from each
patient were quantiﬁed using PicoGreen (Quant-iT; Invitrogen,
Carlsbad, CA) and were pooled together at equal molar ratio.
Library Preparation and Indexing
For each patient, 4 mg of LR-PCR products were pooled
together in a total reaction volume of 210 mL of Tris-EDTA
buffer and were fragmented to approximately 300 bp using
adaptive focused acoustics (Covaris S2; LGC Ltd., Tedding-
ton, UK) with the following settings: duty cycle, 20%; in-
tensity, 5; and cycles per burst, 200. After shearing, the
fragments underwent end repair using the NEBNext end repair
module (New England BioLabs Inc., Ipswich, MA) by adding
30 dAoverhangs to the blunt-endedDNA.After puriﬁcation on
AMPure XP beads, unique indexed adaptors were ligated to
each patient pool using the NEBNext quick ligation module
(New England BioLabs Inc.). Twenty-ﬁve different adapters
with 5-nt bar codes were used for indexing and library prep-
aration. The bar codes located in the 30 end of each adapter
were designed using a published Python script (crea-
te_index_sequences.py)21 with a minimum edit distance, or
mutation tolerance, of three. Each adapter sequence began
with the paired-read oligonucleotide sequences as speciﬁed by
Illumina Inc. (San Diego, CA): 50-GATCGGAAGAGCGG-
TTCAGCAGGAATGCCGAG-30 and 50-ACACTCTTTC-
CCTACACGACGCTCTTCCGATCT-30. Annealing of the
indexed adaptors was performed at 95C for 2 minutes, fol-
lowed by a cooldown to room temperature at a rate of 0.1C
per second using a thermal cycler (Biometra GmbH,217
Tan et alGoettingen, Germany). The ligation products were then puri-
ﬁed with AMPure XP beads and subjected to size selection
using 2% E-Gel SizeSelect (Invitrogen). The selected 500-bp
libraries were then ampliﬁed by PCR using AccuPrime Taq
high ﬁdelity (Invitrogen) with the PCR primers (Illumina Inc.)
50-AATGATACGGCGACCACCGAGATCTACACTCTT-
TCCCTACACGACGCTCTTCCGATCT-30 and 50-CAA-
GCAGAAGACGGCATACGAGATCGGTCTCGGCATTC-
CTGCTGAACCGCTCTTCCGATCT-30 and the following
PCR conditions: 98C for 3 minutes, 10 cycles at 98C (80
seconds), and 65C (90 seconds), followed by a ﬁnal extension
step at 65C for 10 minutes using a thermal cycler (Biometra
GmbH).
Library Pooling and Illumina Sequencing
PCR library products from each patient were puriﬁed with
AMPure XP beads, quantiﬁed, and pooled together at
equimolar amounts in groups of 25 samples. The ﬁnished
libraries were quantiﬁed using the PicoGreen method
(Invitrogen) and were analyzed using the DNA high-
sensitivity chip on an Agilent 2100 Bioanalyzer system
(Agilent Technologies Inc., Santa Clara, CA) for quality
control purposes and for assessing the library size. Each
library pool was then diluted to 10 nmol/L and was loaded
onto a ﬂow cell of the MiSeq system (Illumina Inc.) and
subjected to cluster generation and sequencing using a
paired-end 150-bp cycle protocol according to the manu-
facturer’s instructions. Typically, this read length enables
the detection of indels of approximately 1 to 51 bp using the
computational pipeline. An average MiSeq run generates
6.14 million reads with 5.74 million pass ﬁlter reads, and
77.1% of reads have a high quality score >Q30.Table 1 LR-PCR Primers for NGS Sequencing
Fragment Primers Sequence
PKD1_Ex1 PKD1_NGS_1F 50-CGCAGCCTTACCATCCA
PKD1_NGS_1R 50-TCATCGCCCCTTCCTAA
PKD1_Ex2-12 PKD1_NGS_2-12F 50-CCAGCTCTCTGTCTACT
PKD1_NGS_2-12R 50-CCACGGTTACGTTGTAG
PKD1_Ex13-21 PKD1_NGS_13-21F 50-TGGAGGGAGGGACGCCA
PKD1_NGS_13-21R 50-ACACAGGACAGAACGGC
PKD1_Ex22-34 PKD1_NGS_22-34F 50-ATGCTTAGTGAGGAGGC
PKD1_NGS_22-34R 50-ATGAGGCTCTTTCCACA
PKD1_Ex35-46 PKD1_NGS_35-46F 50-CTGTGGGCGATGGGTTT
PKD1_NGS_35-46R 50-GAGACGGTGCAGGGAGT
PKD2_Ex1 PKD2_NGS_ExP-1_F 50-GTGGAGACAGAAGCCAA
PKD2_NGS_ExP-1_R 50-GGATGCGAGATGGAGCC
PKD2_Ex2 PKD2_NGS_Exon2_F 50-TTTCTTTCCATTTGCAA
PKD2_NGS_Exon2_R 50-GGAAGATAGTCAATAAA
PKD2_Ex3-6 PKD2_NGS_Ex3-6_F 50-GAGAAGACCTTGTGTGA
PKD2_NGS_Ex3-6_R 50-TCATACTCAGCAAAGTT
PKD2_Ex7-10 PKD2_NGS_Ex7-10_F 50-TCGGGTAAGTATAATGG
PKD2_NGS_Ex7-10_R 50-CATCAAGACTCCAAGAT
PKD2_Ex11-15 PKD2_NGS_Ex11-15_F 50-CACGTACTTGTTGAATG
PKD2_NGS_Ex11-15_R 50-ATGAAACTCAGAAGCCC
218Data Analysis Pipeline
For data analysis, Illumina sequencing reads in FASTQ
format were ﬁrst subjected to quality control checks using
the FastQC program (http://www.bioinformatics.babraham.
ac.uk/projects/fastqc, last accessed October 25, 2013). The
reads were then sorted according to their bar code by
FastqMultx22 (https://code.google.com/p/ea-utils/wiki/Fastq
Multx, last accessed November 3, 2013) or the FASTQ/A
barcode splitter program in the FASTX-Toolkit (http://
hannonlab.cshl.edu/fastx_toolkit/index.html, last accessed
October 25, 2013). Reads were then paired-end aligned using
the Burrows-Wheeler Aligner (BWA) program version
0.5.9rc1,23 to a modiﬁed version of the human genome as-
sembly hg19, where all the nucleotides outside the PKD1/
PKD2 loci are masked and replaced with Ns. This procedure
has the advantage of maintaining the genomic coordinates of
the variants and enabling subsequent variant annotation using
standard NGS analysis software (eg, ANNOVAR). Because
the PKD1 pseudogenes are effectively masked, reads cannot be
erroneously mapped to these genomic regions. Sequence var-
iants were called using the Genome Analysis Toolkit (GATK)
software package version 1.6 (Broad Institute, Cambridge,
MA),24 carefully following the best practice guidelines rec-
ommended by GATK,25 including initial read mapping, local
realignment particularly around indels, followed by base
quality score recalibration. Single nucleotide variations (SNVs)
and INDELswere called simultaneously on all 25 samples with
the default setting of GATK Uniﬁed Genotyper on the real-
igned and recalibrated reads, followed by SNV and INDEL
ﬁltering to eliminate false-positive calls. The GATK uses the
Phred scaled probability that a reference/alternative (ALT)
polymorphism exists at a given site (given sequencing data) asSize (kb) Genomic location
CCT-30 2.3 chr16:2185030-2187307
GCA-30
CACCTCCGCATC-30 8.7 chr16:2163080-2171636
TTCACGGTGACG-30
ATC-30 7.9 chr16:2155145-2163036
TGAGGCTA-30
TGTGGGGGTC-30 7.8 chr16:2146980-2154794
GACAACAGAGGTT-30
ATCAGCAG-30 5.2 chr16:2139301-2144473
ACGGTAGGA-30
CCAAAGAG-30 1.4 chr4:88928226-88929584
CG-30
TGTTTCATTC-30 2.5 chr4:88938491-88940897
CAAATGCCCAA-30
ATTTGTCCA-30 10.9 chr4:88957246-88968207
ACTCATGCAAA-30
TGAGCCCT-30 10.3 chr4:88973018-88983323
AGGGAACATTT-30
GCCAATGT-30 10.8 chr4:88986401-88997197
TTTGACAGTT-30
jmd.amjpathol.org - The Journal of Molecular Diagnostics
ADPKD Mutation Analysis by NGSthe main metric for calling polymorphic sites. This metric is
called QUAL in the GATK output, and we require that QUAL
50 together with additional ﬁlters based to deﬁne a site as
PASS. The GATK command line we used is shown in
Supplemental Table S2. For each patient, genotyping likeli-
hoodwas then deﬁned for the AA,A/B, andBB genotypes, and
A/B andBB calls were used as variant calls.We did not specify
a percentage of ALT allele threshold (deﬁned as second
number allelic depth tag in the VCF ﬁle divided by depth of
coverage); however, we determined in postvariant calling an-
alyses that the percentage of ALT allele was >12% for all
variants called. The minimum number of reads supporting the
ALT allele for the called variants was 10. The minimum
depth of coverage for the variants was 39. Given that we
obtained excellent sensitivity and speciﬁcity using currentFigure 1 Visualization of the NGS workﬂow. PKD1 and PKD2 genes were individ
with all coding regions and most intronic regions covered, in total, an approximate
position of the 10 pairs of primers used for LR-PCR ampliﬁcation of the coding regi
and single-copy sequences of PKD1, respectively. B: Ampliﬁcation quality was veriﬁ
were pooled together at equimolar ratio, followed by fragmentation and library p
equimolar amounts in groups of 25 patient samples and were assessed for quality
pooled libraries were sequenced on an Illumina MiSeq platform. The raw sequenc
control analysis before proceeding with the mutation analysis. The quality score (P
mapped back to the PKD1/PKD2 loci of human genome assembly hg19 using the B
Integrative Genomics Viewer (Broad Institute, Cambridge, MA). Red areas, read
F: Variant callings were made by the GATK software package and were visualized
The Journal of Molecular Diagnostics - jmd.amjpathol.orgparameters, as noted in Results, we did not introduce any
additional ﬁlters based on ALT allele percentage but continue
to rely on GATK genotype likelihoods. A variant call was
ﬁltered out with any of the following criteria met: i) SNVs in
clusters (three SNVs within 10 bp of each other), ii) more
than four reads with mapping quality of zero and >10% of
reads with mapping quality of zero, iii) strand bias higher
than or equal to 1.0, iv) SNV quality score <30,
v) quality-by-depth score <1.5, vi) largest contiguous ho-
mopolymer run of variant allele >10, and vii) depth of
coverage less than ﬁvefold. After ﬁltering, variant calls
were annotated using ANNOVAR software version 2012,26
and the ﬁnal genotyping reports were then generated. The
entire data analysis pipeline was automated using Unix shell
scripts, with raw lllumina sequencing as input and ﬁnalually ampliﬁed as 10 locus-speciﬁc LR-PCR products (1.4 to 10.9 kb in size),
ly 68.0 kb genomic region. A: Map of the PKD1 and PKD2 genes showing the
ons. The highlighted green and yellow regions correspond to the duplicated
ed using agarose gel electrophoresis. C: LR-PCR products from each patient
reparation. The ﬁnished libraries were quantiﬁed and batched together at
by a high-sensitivity chip using an Agilent Bioanalyzer instrument. D: The
ing reads were sorted by bar code ﬁrst and then were subjected to quality
hred-like score) is shown at each position of the reads. E: Reads were then
WA program. In this example, PKD1 sequencing coverage is shown using the
s from the plus DNA strands; blue areas, reads from the minus strands.
using the Integrative Genomics Viewer. Ex, exon; FU, ﬂuorescence unit.
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Figure 2 Illustration of the data analysis pipelines. Listed are the
analysis steps (A) and the corresponding software/application programs
involved (B).
Figure 3 Read depth and coverage analysis results. Plot shows the base
coverage (y axis) of each LR-PCR amplicon of the PKD1 and PKD2 genes of
one patient. The x axis represents the genomic interval. The average read
depth for each fragment is indicated under each amplicon. The plots were
generated using the Integrative Genomics Viewer. Ex, exon.
Tan et algenotyping reports as output. In the present study, we
restricted analysis to the coding exons and 20 bp of the
ﬂanking intronic regions. Statistical computations were
performed using R version 3.0.1 software (The R Founda-
tion for Statistical Computing, http://www.r-project.org).
Assay Analytical Characteristics
An evaluation of the assay analytical characteristics was
performed using only variants located in regions analyzed
by both NGS and Sanger sequencing and compared herein.
Positive results were deﬁned as all variant alleles detected
by NGS in the 25-patient cohort. Negative results were
deﬁned as genotypes identical to the reference sequence at
genomic sites where variants are found across the 25 pa-
tients. The new assay was evaluated for sensitivity and
speciﬁcity using the following formulas:
Sensitivity Z number of true-positives/(number of true-
positives þ number of false-negatives),
Speciﬁcity Z number of true-negatives/(number of true-
negatives þ number of false-positives).
Reference Sequences, Variant Nomenclature, and
Variant of Uncertain Signiﬁcance Scoring
NCBI RefSeq sequences were used for reference sequence:
PKD1, NM_000296.3; PKD2, NM_000279.3. The standard
nomenclature recommended by the Human Genome Vari-
ation Society (http://www.hgvs.org/mutnomen, last accessed
October 25, 2013)27 was used to number nucleotides and
name mutations or variants. All sequence variant de-
scriptions were checked for accuracy using the Mutalyzer
2.0 program (http://www.mutalyzer.nl/2.0, last accessed
October 25, 2013). Variants of uncertain signiﬁcance were
classiﬁed based on computational analysis scores as previ-
ously described.18220Results
LR-PCReBased NGS Analysis of Pooled Control Samples
To improve ADPKD testing and eliminate the need for
Sanger sequencing, we used an LR-PCR NGS strategy to
speciﬁcally amplify and directly sequence the entire coding
region of both PKD1 and PKD2 genes for up to 25 patients
in a single sequencing reaction. An overview of the NGS
workﬂow is shown in Figure 1, which includes a diagram
of the PKD genes and the relative primer pair positions,
LR-PCR enrichment and product analysis, and data anal-
ysis steps. The unique LR-PCR oligonucleotides have been
carefully designed to cover approximately 67.8 kb of
genomic sequence, including all exonic sequences and
ﬂanking intronic regions (see Materials and Methods).
Agarose gel electrophoresis with ethidium bromide stain-
ing of the LR-PCR products demonstrated speciﬁc frag-
ments ranging in size from 1.4 to 10.8 kb, each covering 1
to 11 exons corresponding to the sequence of PKD1 and
PKD2 (Figure 1). For evaluating the NGS workﬂow, we
pooled individually bar-coded sequencing libraries from
up to 25 patients onto a single ﬂow cell of the MiSeq
system (Illumina Inc.) and subjected it to cluster generation
and sequencing using paired-end sequencing. We analyzed
the sequencing results using an automated NGS data
analysis pipeline combining the FastQC, FASTX-Toolkit,
BWA, GATK, and ANNOVAR software packages, as
illustrated in Figure 2. The Sanger sequencingeveriﬁed
gene variations allowed a detailed analysis of read depth
(number of reads per known variant), coverage (percentage
of the regions of interest adequately covered), sensitivity
(proportion of true-positives), and speciﬁcity (proportion
of true-negatives).
Using this approach, 85% of all sequenced reads mapped to
the PKD1/2 reference genome. Of these mapped reads, 100%
mapped back to the targeted PKD1 and PKD2 regions.
Overall, a very high read depth was obtained across all PKD
gene target regions, with>93% of targeted sequences covered
with >30 for the entire amplicon. Focusing on exonicjmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 4 Visualization of typical PKD1 NGS
gene variation calls. A nonsense mutation (A) and
a 10-bp deletion variant (B) are shown. NGS reads
were piled up and are shown on the Integrative
Genomics Viewer on top; Sanger sequencing con-
ﬁrmations are shown below.
ADPKD Mutation Analysis by NGSregions, we calculated the minimum, maximum, and average
read depth for all PKD1 and PKD2 exons extending 20 bp
from each end. This analysis demonstrated that except for two
patients with a failed PCR product encompassing a single exon
and PKD1 exon 1 (see below for explanation), all the exons
hadminimum coverage11, average coverage103, and
maximum coverage 127. For most exons (53 of 60),
minimum coveragewas50. Theminimum,maximum, and
average read depths as well as quality metrics for all the exons
are provided in Supplemental Tables S3 and S4, respectively.
For PKD1 exon 1, which contains a highly GC-rich region
centered approximately on the start codon, there was a low
minimum coverage in several of the patients (down to 0 at
one to two nucleotides). The length of the poorly covered
region (deﬁned as a region in which one or more patients
had <5 coverage) was 156 bp (chr16:2185623-2185778),
suggesting that, except for this sequence, accurate variant
calling is possible across all the PKD1 and PKD2 exons.
Representative read depth and coverage analysis results are
shown in Figure 3. For this typical sample, 100% of the
targeted region was covered>15-fold depth, and 93% of the
targeted region was covered >30-fold depth, with PKD1
exon 1 having the lowest read depth because of its ex-
tremely high GC content (approximately 85%) and low
complexity.
Based on these results, SNVs and small insertion/deletion
variants (three deletions of 10, 4, and 2 bp in length and one
24-bp-long insertion) (Figure 4) were detected, indicating
that multiplexing of LR-PCR libraries did not compromise
sensitivity or speciﬁcity rates.Figure 5 Distribution of the ALT allele frequencies. The analysis was
performed using R software version 3.0.1 (http://www.r-project.org). The
results are shown as a function of the ALT allele frequency percentage.NGS Variant Analysis
Using this method, we validated a cohort of 25 patients who
have been previously genotyped by Sanger sequencing. The
samples selected harbored gene variations spanning the entire
genetic sequence of PKD1 and PKD2. Data mining hasThe Journal of Molecular Diagnostics - jmd.amjpathol.orgcorrectly identiﬁed all 250 Sanger sequencing changes (cor-
responding to 83 gene variations), indicating that the NGS
method has a diagnostic performance comparable with that of
the direct sequencing approach currently used in our labora-
tory (Weill Cornell Medical College Molecular Pathology
Research Laboratory, New York, NY). However, in one of
these patients, two changes (PKD1 c. 7165T>C:p.Z and
PKD1 c. 6598 C>T:p.R2200C) were incorrectly identiﬁed as
homozygous by NGS rather than as heterozygous. Further
investigation using Sanger sequencing of the NGS LR-PCR
product revealed that both variants were located in the same
amplicon and that the miscalling resulted from allele dropout
of the reference allele (data not shown).
Investigation of the distribution of the ALT alleles showed
two sharp peaks centered on 50% ALT frequency and near
100% frequency (Figure 5). Most variants (90.5%) were within
the expected 40% to 60%or>90%ALTallele frequency range.
We identiﬁed 16 variants with<40%ALT allele frequency. Of
these, two variants had relatively low coverage (56 and 39),221
Table 2 Details of PKD1 and PKD2 Variants Analyzed in the Cohort of 25 Sanger SequencingeConﬁrmed Patients with ADPKD Analyzed by NGS
Chromo-
some Position dbSNP ID REF ALT Gene
Exon/
Intron Function Variant nomenclature QUAL FILTER
16 2139875 rs62038811 G A PKD1 Exon46 Synonymous SNV NM_000296.3:c.12762C>T:p.Z 4925.23 PASS
16 2140010 rs7203729 A G PKD1 Exon46 Synonymous SNV NM_000296.3:c.12627T>C:p.Z 11,757.62 PASS
16 2140177 A C PKD1 Exon46 Nonsynonymous SNV NM_000296.3:c.12460T>G:p.F4154V 5601.09 PASS
16 2140321 rs79899502 G A PKD1 Exon45 Synonymous SNV NM_000296.3:c.12406C>T:p.Z 10007.98 PASS
16 2140454 rs3087632 T C PKD1 Exon45 Synonymous SNV NM_000296.3:c.12273A>G:p.Z 28352.74 PASS
16 2140554 rs3209986 G A PKD1 Exon45 Nonsynonymous SNV NM_000296.3:c.12173C>T:p.A4058V 11352.25 PASS
16 2140680 rs10960 T C PKD1 Exon44 Nonsynonymous SNV NM_000296.3:c.12130A>G:p.I4044V 28827.19 PASS
16 2141454 G A PKD1 Exon42 Synonymous SNV NM_000296.3:c.11679C>T:p.Z 2940.32 PASS
16 2141522 C A PKD1 Exon42 Stopgain SNV NM_000296.3:c.11611G>T:p.E3871X 4450.2 PASS
16 2142573 C G PKD1 Exon39 Nonsynonymous SNV NM_000296.3:c.11174G>C:p.W3725S 4102.69 PASS
16 2144026 GA G PKD1 Intron35 Intronic deletion NM_000296.3:c.10616-13delT 6754.83 PASS
16 2144123 G A PKD1 Exon35 Stopgain SNV NM_000296.3:c.10585C>T:p.Q3529X 2175.31 PASS
16 2144176 rs34197769 G A PKD1 Exon35 Nonsynonymous SNV NM_000296.3:c.10532C>T:p.A3511V 6720.4 PASS
16 2147518 G A PKD1 Intron32 Intronic SNV NM_000296.3:c.10218-14C>T 6194.41 PASS
16 2150323 / A G PKD1 Intron27 Intronic SNV NM_000296.3:c.9569-13T>C 6960.57 PASS
16 2150489 GCT G PKD1 Exon27 Frameshift deletion NM_000296.3:c.9474_9475del:
p.3158_3159del
7103.23 PASS
16 2152129 / A G PKD1 Exon26 Synonymous SNV NM_000296.3:c.9330T>C:p.Z 64581.14 PASS
16 2152387 / A G PKD1 Exon25 Nonsynonymous SNV NM_000296.3:c.9196T>C:p.F3066L 49993.66 PASS
16 2152388 / C G PKD1 Exon25 Synonymous SNV NM_000296.3:c.9195G>C:p.Z 50653.93 PASS
16 2152619 / C T PKD1 Exon25 Synonymous SNV NM_000296.3:c.8964G>A:p.Z 7886.09 PASS
16 2152651 / T C PKD1 Intron24 Intronic SNV NM_000296.3:c.8949-17A>G 41146.96 PASS
16 2152847 / G A PKD1 Exon24 Synonymous SNV NM_000296.3:c.8916C>T:p.Z 7036.67 PASS
16 2153272 A See
below*
PKD1 Exon23 Nonframeshift
insertion
See below* 33209.17 PASS
16 2153618 / C T PKD1 Exon23 Nonsynonymous SNV NM_000296.3:c.8440G>A:p.G2814R 3477.3 PASS
16 2153619 / G A PKD1 Exon23 Synonymous SNV NM_000296.3:c.8439C>T:p.Z 4679.38 PASS
16 2153765 / G A PKD1 Exon23 Nonsynonymous SNV NM_000296.3:c.8293C>T:p.R2765C 4200.12 PASS
16 2154537 / G A PKD1 Exon22 Nonsynonymous SNV NM_000296.3:c.8123C>T:p.T2708M 3605.52 PASS
16 2154565 G A PKD1 Exon22 Stopgain SNV NM_000296.3:c.8095C>T:p.Q2699X 3154.68 PASS
16 2155426 / T C PKD1 Exon21 Nonsynonymous SNV NM_000296.3:c.7913A>G:p.H2638R 32433.16 PASS
16 2156021 / A G PKD1 Exon20 Synonymous SNV NM_000296.3:c.7708T>C:p.Z 45989.17 PASS
16 2156447 / G A PKD1 Exon18 Synonymous SNV NM_000296.3:c.7441C>T:p.Z 39665.05 PASS
16 2156623 G T PKD1 Exon18 Nonsynonymous SNV NM_000296.3:c.7265C>A:p.T2422K 1634.58 PASS
16 2156850 / A G PKD1 Exon17 Synonymous SNV NM_000296.3:c.7165T>C:p.Z 90944.82 PASS
16 2158022 / G A PKD1 Exon16 Synonymous SNV NM_000296.3:c.6927C>T:p.Z 5649.07 PASS
16 2158570 / G A PKD1 Exon15 Nonsynonymous SNV NM_000296.3:c.6598C>T:p.R2200C 28297.7 PASS
16 2158871 / C A PKD1 Exon15 Synonymous SNV NM_000296.3:c.6297G>T:p.Z 7173.93 PASS
16 2159313 C T PKD1 Exon15 Nonsynonymous SNV NM_000296.3:c.5855G>A:p.G1952D 8717.56 PASS
16 2159321 / G A PKD1 Exon15 Synonymous SNV NM_000296.3:c.5847C>T:p.Z 3863.12 PASS
16 2159391 G A PKD1 Exon15 Nonsynonymous SNV NM_000296.3:c.5777C>T:p.A1926V 2041.5 PASS
16 2159405 / C T PKD1 Exon15 Synonymous SNV NM_000296.3:c.5763G>A:p.Z 6637.77 PASS
16 2159557 / C T PKD1 Exon15 Nonsynonymous SNV NM_000296.3:c.5611G>A:p.A1871T 4010.9 PASS
16 2159996 / G A PKD1 Exon15 Synonymous SNV NM_000296.3:c.5172C>T:p.Z 47423.27 PASS
16 2160280 G A PKD1 Exon15 Stopgain SNV NM_000296.3:c.4888C>T:p.Q1630X 6618.24 PASS
16 2160494 / C T PKD1 Exon15 Synonymous SNV NM_000296.3:c.4674G>A:p.Z 19874.71 PASS
16 2160503 / T G PKD1 Exon15 Synonymous SNV NM_000296.3:c.4665A>C:p.Z 49280.48 PASS
16 2160622 / C T PKD1 Exon15 Nonsynonymous SNV NM_000296.3:c.4546G>A:p.A1516T 3201.27 PASS
16 2160673 / G A PKD1 Exon15 Synonymous SNV NM_000296.3:c.4495C>T:p.Z 3420.25 PASS
16 2160716 C T PKD1 Exon15 Synonymous SNV NM_000296.3:c.4452G>A:p.Z 3964.01 PASS
16 2160973 / A G PKD1 Exon15 Nonsynonymous SNV NM_000296.3:c.T4195C:p.W1399R 32607.04 PASS
16 2161244 CTGCGT-
GGGGA
C PKD1 Exon15 Frameshift deletion NM_000296.3:c.3914_3923del:
p.1305_1308del
7343.71 PASS
16 2161443 G A PKD1 Exon15 Nonsynonymous SNV NM_000296.3:c.3725C>T:p.T1242M 3864.26 PASS
16 2161655 / G C PKD1 Exon15 Synonymous SNV NM_000296.3:c.3513C>G:p.Z 2905.22 PASS
16 2161793 / G A PKD1 Exon15 Synonymous SNV NM_000296.3:c.3375C>T:p.Z 33353.67 PASS
16 2161796 / G A PKD1 Exon15 Synonymous SNV NM_000296.3:c.3372C>T:p.Z 33778.82 PASS
16 2161874 T G PKD1 Intron14 Splicing SNV NM_000296.3:c.3296-2A>C 3192.03 PASS
16 2162361 / A G PKD1 Exon14 Nonsynonymous SNV NM_000296.3:c.3275T>C:p.M1092T 31648.89 PASS
16 2162839 / T C PKD1 Exon13 Synonymous SNV NM_000296.3:c.3111A>G:p.Z 11160.46 PASS
16 2162887 / A G PKD1 Exon13 Synonymous SNV NM_000296.3:c.3063T>C:p.Z 22392.19 PASS
16 2164294 / G A PKD1 Exon11 Synonymous SNV NM_000296.3:c.2730C>T:p.Z 11471.01 PASS
(table continues)
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Table 2 (continued )
Chromo-
some Position dbSNP ID REF ALT Gene
Exon/
Intron Function Variant nomenclature QUAL FILTER
16 2164324 / C T PKD1 Exon11 Synonymous SNV NM_000296.3:c.2700G>A:p.Z 11,448.82 PASS
16 2164330 / T G PKD1 Exon11 Synonymous SNV NM_000296.3:c.2694A>C:p.Z 4682.76 PASS
16 2164808 / C T PKD1 Exon11 Nonsynonymous SNV NM_000296.3:c.2216G>A:p.R739Q 279070.57 PASS
16 2165630 / T C PKD1 Intron9 intronic SNV NM_000296.3:c.1850-4A>G 50257.02 PASS
16 2166061 A T PKD1 Exon9 Nonsynonymous SNV NM_000296.3:c.1781T>A:p.F594Y 4476.37 PASS
16 2167874 G A PKD1 Exon5 Synonymous SNV NM_000296.3:c.1119C>T:p.Z 268925.84 PASS
16 2167970 G A PKD1 Exon5 Synonymous SNV NM_000296.3:c.1023C>T:p.Z 12263.35 PASS
16 2169178 C A PKD1 Exon3 Nonsynonymous SNV NM_000296.3:c.296G>T:p.S99I 8791.34 PASS
16 2185509 G A PKD1 Exon1 Nonsynonymous SNV NM_000296.3:c.182C>T:p.P61L 750.13 PASS
16 2185584 G T PKD1 Exon1 Nonsynonymous SNV NM_000296.3:c.107C>A:p.P36H 127.59 PASS
4 88928968 rs1805044 G C PKD2 Exon1 Nonsynonymous SNV NM_000297.3:c.83G>C:p.R28P 41620.06 PASS
4 88929080 G GGACC PKD2 Exon1 Frameshift insertion NM_000297.3:c.195_196insGACC:
p.R65fs
10644.57 PASS
4 88929082 A AC PKD2 Exon1 Frameshift insertion NM_000297.3:c.197_198insC:
p.D66fs
4694.47 PASS
4 88929305 rs2728118 G A PKD2 Exon1 Synonymous SNV NM_000297.3:c.420G>A:p.Z 5295.98 PASS
4 88929453 rs117078377 G A PKD2 Exon1 Nonsynonymous SNV NM_000297.3:c.568G>A:p.A190T 4083.65 PASS
4 88940594 rs62310565 C T PKD2 Intron1 Intronic SNV NM_000297.3:c.596-16C>T 2722.03 PASS
4 88959475 C T PKD2 Exon4 Stopgain SNV NM_000297.3:c.916C>T:p.R306X 5216.94 PASS
4 88959479 GT G PKD2 Exon4 Frameshift deletion NM_000297.3:c.921delT:p.S307fs 10175.19 PASS
4 88959517 C T PKD2 Exon4 Stopgain SNV NM_000297.3:c.958C>T:p.R320X 3946.43 PASS
4 88959653 CGTAA C PKD2 Intron4 Splicing deletion NM_000297.3:c.1094D1_1094D4del 8740.89 PASS
4 88964610 G A PKD2 Intron5 Splicing SNV NM_000297.3:c.1319D1G>A 8073.4 PASS
4 88967919 rs75762896 T G PKD2 Exon6 Nonsynonymous SNV NM_000297.3:c.1445T>G:p.F482C 6455.92 PASS
4 88977424 G A PKD2 Intron8 Intronic SNV NM_000297.3:c.1898þ5G>A 7426.45 PASS
4 88996055 C T PKD2 Exon14 Stopgain SNV NM_000297.3:c.2614C>T:p.R872X 3914.06 PASS
Pathogenic mutations are denoted in bold.
*AGCAGCGTATAGTTGAGCTGCAGAT; variant nomenclature, NM_000296.3:c.8786_8787insATCTGCAGCTCAACTATACGCTGC:p.L2929delinsHLQLNYTLL.
REF, reference; /, there was entry in dbSNP but was removed because it was located in PKD1 duplicated region thus could be contamination from pseudogenes.
ADPKD Mutation Analysis by NGSwhich could have led to inaccurate ALT frequency estimation.
The 14 remaining low ALT percentage variants had coverage
similar to the other variants and were spread across six distinct
patients. Three low ALT percentage variants were repeatedly
found in four patients. These three variants are known single
nucleotide polymorphisms (SNPs) (rs10960, rs3087632, and
rs7203729) and are found in other patients at frequencies in the
40% to 60% or >90% ALT allele frequency range. All three
variants are within 700 bp of each other on chromosome 16
(positions 2140010, 2140454, and 2140680). Visual inspection
of these low ALT percentage variants did not reveal any
sequence artifacts; eg, the regions around these SNPs were
neither GC poor nor GC rich, suggesting preferential ampliﬁ-
cation of the normal allele during LR-PCR. A detailed list of all
PKD1 and PKD2 genetic variations identiﬁed in this study and
an assessment of the pathogenic potential ofmissense variants in
ANNOVARsoftware are shown inTables 2 and 3, respectively.
Of these 250 variants, 221 (88.4%) were in PKD1 and 29
(11.6%) were in PKD2, and 16 variants were pathogenic
(Table 2). The analytic sensitivity and speciﬁcity were calcu-
lated for 2075 sites in aggregate across the 25 samples (corre-
sponding to 83 target locations in 25 patients), including 250
variants and 1825 normal alleles, that matched the reference
genes. The sensitivity of the NGSmethod was 99.2% (95% CI,
96.8%e99.9%) and the speciﬁcity was 99.9% (95% CI,
99.7%e100.0%) compared with Sanger sequencing results
(Table 4). Taken together, these results suggest that pooling 25The Journal of Molecular Diagnostics - jmd.amjpathol.orgbar-coded samples in a single Illumina run is feasible, with an
expected read depth of approximately 300-fold.
Mutation Analyses of Pathogenic Mutation-Negative
and Novel Patients with ADPKD by Bar-Coded and
Multiplexed NGS
Based on these proof-of-principle results, we analyzed an
additional 24 ADPKD cases that tested negative for a patho-
genic mutation by Sanger sequencing. The NGS method
identiﬁed PKD1 pathogenic variants in three patients for whom
variants were not previously detected (NM_000296.3:c.3296-
2A>T; NM_000296.3:c. 7288 C>T:p.R2430X; and
NM_000296.3:c. 1937 G>A:p.W646X), which were then
further conﬁrmed by Sanger sequencing. One of these variants,
NM_000296.3:c.3296-2A>T, was previously missed because
of a technologist’s error, whereas the other two were mainly
due to allele dropout during the LR-PCR step. Careful analysis
of the original Sanger sequencing data demonstrated very low
signal (<10% to 20%) for the mutant alleles, leading to mis-
called sequences.
To further evaluate the sensitivity and speciﬁcity of the
NGS assay, we analyzed an additional cohort of 25 patients
with ADPKD that had not been previously genotyped. Of the
25 patients, 16 (64%) had a pathogenic or probably patho-
genic mutation, whereas no mutations were identiﬁed in the
remainder of the patient cohort (Table 5). All the positive223
Table 4 NGS Analytic Sensitivity and Speciﬁcity (Variants
Detection)
NGS
Sanger sequencing
Variant
alleles
(positive)
Reference
alleles
(negative) Total
Variant alleles (positive) 248 0 248
Reference alleles (negative) 2 1825 1827
Total 250 1825 2075
Compared with the Sanger sequencing assay: sensitivityZ 99.2% (95%
CI, 96.8%e99.9%); speciﬁcity Z 99.9% (95% CI, 99.7%e100.0%).
Table 3 Assessment of the Pathogenic Potential of Missense Variants in the ANNOVAR Program
Gene Amino acid change
Frequency in
1000 Genome
Project dbSNP132
SIFT
prediction
PolyPhen-2
prediction
Mutation
Taster
prediction
Overall
prediction
PKD1 NM_000296.3:c.296G>T:p.S99I D D D PP
PKD1 NM_000296.3:c.7265C>A:p.T2422K D D D PP
PKD1 NM_000296.3:c.8123C>T:p.T2708M D D D PP
PKD1 NM_000296.3:c.12460T>G:p.F4154V D D D PP
PKD1 NM_000296.3:c.11174G>C:p.W3725S D D D PP
PKD1 NM_000296.3:c.7913A>G:p.H2638R T B N NE
PKD1 NM_000296.3:c.4546G>A:p.A1516T T B N NE
PKD1 NM_000296.3:c.12130A>G:p.I4044V 0.23 rs10960 T B N NE
PKD1 NM_000296.3:c.2216G>A:p.R739Q T B N NE
PKD1 NM_000296.3:c.10532C>T:p.A3511V 0.06 rs34197769 T B N NE
PKD1 NM_000296.3:c.3275T>C:p.M1092T T B N NE
PKD1 NM_000296.3:c.5777C>T:p.A1926V T B N NE
PKD1 NM_000296.3:c.4195T>C:p.W1399R T B N NE
PKD1 NM_000296.3:c.8440G>A:p.G2814R T P N PN
PKD1 NM_000296.3:c.107C>A:p.P36H T NA N NE
PKD1 NM_000296.3:c.5855G>A:p.G1952D D P N PN
PKD1 NM_000296.3:c.182C>T:p.P61L D P N PN
PKD1 NM_000296.3:c.12173C>T:p.A4058V 0.03 rs3209986 T D N PN
PKD1 NM_000296.3:c.1781T>A:p.F594Y T D N PN
PKD1 NM_000296.3:c.5611G>A:p.A1871T T D N PN
PKD1 NM_000296.3:c.9196T>C:p.F3066L T D N PN
PKD1 NM_000296.3:c.8293C>T:p.R2765C D D N PN
PKD1 NM_000296.3:c.3725C>T:p.T1242M D D N PN
PKD1 NM_000296.3:c.6598C>T:p.R2200C D D N PN
PKD2 NM_000297.3:c.1445T>G:p.F482C 0.003 rs75762896 D D D D
PKD2 NM_000297.3:c.568G>A:p.A190T 0.07 rs117078377 T P N NE
PKD2 NM_000297.3:c.83G>C:p.R28P 0.14 rs1805044 D P N PN
B, benign; D, deleterious; N, neutral; NA, not available; NE, neutral (sequence changes scored as benign by all three software applications18); P, possibly
damaging; PP, probably pathogenic (sequence changes scored as deleterious by all three computational analysis tools18); PN, probably neutral (sequence
changes scored as benign by only one or two of the software applications18); T, tolerant.
Tan et alresults and the mutation-negative cases were conﬁrmed by
Sanger sequencing, suggesting sensitivity and speciﬁcity of
100% for detecting ADPKD mutations in this sample.
NGS Cost Analysis
We also evaluated the costs of reagents and sequencing for the
NGS-based approach. By pooling 25 patient samples in a
single NGS Illumina MiSeq run, the cost of the test was
reduced by approximately 70% compared with Sanger
sequencing, from approximately $271 per patient to approxi-
mately $82 per patient (Table 6). Moreover, although the
hands-on time required for setting up the LR-PCR reactions,
preparing the library, and sequencing still requires approxi-
mately 1 week, data analysis is considerably faster with NGS
than with the Sanger method and can be completed in only a
few hours. Therefore, a 25-patient cohort could be analyzed in
1 to 2weeks comparedwith4weekswith the Sangermethod.
Discussion
NGS technology has revolutionized genomic and genetic
research and the ﬁeld of clinical genomics. Sample bar224coding and multiplexing capabilities and the availability of
simpler workﬂows and faster turnaround time instruments,
such as Illumina MiSeq, have made this method attractive to
clinical laboratories. Rossetti et al17 recently developed an
original approach for PKD gene mutation detection in large
cohorts by coupling LR-PCR with NGS analysis with
sensitivity of 78% and speciﬁcity of 100%. Herein, we
describe a new NGS PKD genotyping approach with
analytical sensitivity of 99.2% and speciﬁcity of 99.9%
compared with the Sanger sequencing method. Thisjmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 5 Details of PKD1 and PKD2 Mutations in a Cohort of 25 Novel Patients
No. Chr. Position REF ALT Exon Gene Exonic function Amino acid change QUAL FILTER
1 16 2141440 CAGCG C 42 PKD1 Frameshift deletion NM_000296.3:c.11690_11693del:
p.3897_3898del
11,229.66 PASS
2 16 2157900 CT C 16 PKD1 Frameshift deletion NM_000296.3:c.7049delA:p.E2350fs 16754.66 PASS
3 16 2144151 GCCCCA-
GCTCC
G 35 PKD1 Frameshift deletion NM_000296.3:c.10548_10557del:
p.3516_3519del
32720.66 PASS
4 16 2168287 G A 5 PKD1 Stopgain SNV NM_000296.3:c. 706C >T:p.Q236X 6574.71 PASS
5 16 2164185 G A 11 PKD1 Stopgain SNV NM_000296.3:c. 2839 C>T:p.Q947X 9480.71 PASS
6 16 2156600 G A 18 PKD1 Stopgain SNV NM_000296.3:c. 7288 C>T:p.R2430X 4314.5 PASS
7 16 2140782 G A 44 PKD1 Stopgain SNV NM_000296.3:c. 12028 C>T:p.Q4010X 13180.82 PASS
8 16 2160674 G T 15 PKD1 Stopgain SNV NM_000296.3:c. 4494 C>A:p.Y1498X 9530.5 PASS
9 16 2166531 T A 8 PKD1 Nonsynonymous SNV*y NM_000296.3:c. 1721 A>T:p.E574V 6856.71 PASS
10 16 2156912 A G 17 PKD1 Nonsynonymous SNV* NM_000296.3:c. 7103 T>C:p.L2368S 16,133.71 PASS
11 16 2164844 A G 11 PKD1 Nonsynonymous SNV* NM_000296.3:c. 2180 T>C:p.L727P 7176.71 PASS
12 4 88929082 A AC 1 PKD2 Frameshift insertion NM_000297.3:c.197_198insC:p.D66fs 10197.45 PASS
13 4 88959475 C T 4 PKD2 Stopgain SNV NM_000297.3:c. 916 C>T:p.R306X 11,046.71 PASS
14 4 88959517 C T 4 PKD2 Stopgain SNV NM_000297.3:c. 958 C>T:p.R320X 18,191.71 PASS
15 4 88929145 G A 1 PKD2 Stopgain SNV NM_000297.3:c. 260 G>A:p.W87X 4583.71 PASS
16 4 88959536 T G 4 PKD2 *Nonsynonymous SNV NM_000297.3:c. 977 T>G:p.V326G 11,941.71 PASS
*Classiﬁed as probably pathogenic based on SIFT, Polyphen-2, and MutationTaster predictions as speciﬁed in Materials and Methods.
yPredicted to affect exon splicing by computational analysis by distrusting an exonic splice enhancer.
Chr, chromosome; REF, reference.
ADPKD Mutation Analysis by NGSapproach is based on LR-PCR ampliﬁcation of both the
PKD1 and PKD2 genes using 10 pairs of carefully designed
PCR primers covering approximately 68.0 kb of PKD
genomic region, corresponding to 31.9 kb (68.8%) and 35.8
kb (51.0%) of the PKD1 and PKD2 genomic regions,
respectively, particularly tailored to relatively small cohorts
and clinical diagnostic applications. This improvement in
sensitivity is mainly due to two factors. First, we individually
bar coded LR-PCR products by patient rather than pooling of
DNA samples or LR-PCR amplicons from different patients
before sample bar coding.17 In contrast, Rossetti et al17
pooled DNA samples or PCR products before libraryTable 6 Comparison of Reagents, Sequencing Costs, and Time of Labo
Method Purpose Qua
Sanger sequencing (N Z 25) LR-PCR (PKD1) 25
Standard PCR (PKD2) 40
Puriﬁcation 20
Sequencing primers 305
Sanger sequencing 160
Data analysis NA
Total
NGS (N Z 25) LR-PCR (PKD1 and PKD2) 25
LR-PCR product quantiﬁcation 25
DNA fragmentation 2
Library preparation 2
Library quality assessment 2
NGS sequencing (MiSeq)
Data analysis NA
Total
NA, not applicable.
The Journal of Molecular Diagnostics - jmd.amjpathol.orggeneration, leading to a substantial loss of sensitivity and
speciﬁcity due primarily to lack of coverage. The strategy
used in the present study allows for improved coverage of
individual patient samples by increasing read depth and
decreasing background noise, thus allowing variant calls with
high conﬁdence. Second, we used longer reads on the MiSeq
platform (150 bp  2 as opposed to 101 bp/75 bp  2)
compared with Rossetti et al,17 ensuring higher genome
mapping accuracy by reducing mapping errors.
We used the GATK software package to reﬁne the BAM
(Binary Alignment/Map) ﬁle generated by the BWA pro-
gram; this step can improve accuracy in variant calls,r for Sanger Sequencing and NGS
ntity
Cost ($) Labor time
(days)Per sample Per run Per subject
0 2.40 600.00 24.00 5
0 1.50 600.00 24.00 4
0 2.40 480.00 19.20 1
0 0.10 305.00 12.20 NA
0 3.00 4800.00 192.00 5
NA NA NA 4
6785.00 271.40 19
0 1.45 362.50 14.50 2
0 0.12 30.00 1.20 0.5
5 6.50 162.50 6.50 0.5
5 20.00 500.00 20.00 3
5 0.20 5.00 0.20 0.25
1 990.00 990.00 39.60 1
NA NA NA 1
2050.00 82.00 8.25
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Figure 6 Coverage plot illustrating the identiﬁcation of a large-sized
deletion in PKD2. The patient had an approximately 6-kb deletion that
included PKD2 exon (Ex) 5 and adjacent intronic regions compared with the
control sample.
Tan et alparticularly for indels. Variant calling of NGS data is prone
to a high error rate owing to the following factors: many
reads spanning insertion/deletion sites are misaligned
because each read is aligned independently, and the raw
base quality scores often vary with instrument features, such
as the platform used, machine cycle, and sequence context,
and, thus, cannot reﬂect the true base calling error rates.25
These errors in alignments and base calling will be trans-
lated into variant and genotype inference, leading to false
sequence calls. The local realignment around indels and
base quality score recalibration function in the GATK
package can decrease the false-positive calls around indels,
increasing base quality at the end of the reads and enabling
overall higher accuracy of the sequence data.25 Furthermore,
the multiple sampleecalling feature of GATK enabled
processing of multiple samples simultaneously, allowing the
use of sequencing information across all samples, further
increasing the accuracy of variant call. Liu et al28 conducted
a systematic assessment of several variant calling packages
and found that GATK in combination with the BWA aligner
performed better compared with other software applications
for high coverage of Illumina data (20). The present
NGS data had average coverage of 103, far above the
threshold, making it suitable for these analyses.
The alignment algorithm in the analysis pipeline, BWA,
is a fast and memory-efﬁcient short read aligner,23 allowing
implementation on a standard desktop computer without the
need for expensive computer clusters and making it attrac-
tive to the standard diagnostic laboratory. In our experience,
data from 25 patients could be efﬁciently analyzed (within
several hours) using an iMac desktop computer with two
processors and a 3.06-GHz CPU and 16 GB of memory
(Apple Inc., Cupertino, CA). The data analysis pipelines
have been fully automated with Unix shell scripts, signiﬁ-
cantly reducing the hands-on time required for quality
checks of the sequencing data. This is a major improvement
compared with the labor-intensive pipeline required for
analyzing Sanger sequencing data, even when using auto-
mated applications, such as Mutation Surveyor (SoftGe-
netics LLC., State College, PA),13 for variant calling.
Moreover, ANNOVAR genomic annotator can readily ac-
cess several prediction programs, including SIFT,29 Poly-
Phen-2,30 and Mutation Taster (http://www.mutationtaster.
org, last accessed October 25, 2013),31 used for evalu-
ating the pathogenic potential of missense change, providing
important information about the pathogenicity of the vari-
ants analyzed. In this study, of 27 missense variants, six
were classiﬁed as deleterious by all three prediction algo-
rithms, which is in agreement with the results obtained by
the present standard bioinformatics procedures (Table 3).18
Taken together, the workﬂow reported herein can be
easily adapted to a routine clinical diagnostic setting. The
LR-PCR and library preparation steps have been automated
using a liquid handler (Corbett 1200; Qiagen Inc.), stan-
dardizing the reaction setup process. Similarly, the indi-
vidual bar coding of patient samples and the simultaneous226processing of 25 samples, together with the automated data
analysis pipeline, have greatly reduced the number of test
reactions, decreasing technologist’s errors and increasing
the overall precision and accuracy of the sequencing data
obtained. Consequently, up to 25 patients can be genotyped
in 1 to 2 weeks at reagent costs of $82 per patient compared
with $271 per patient with the current Sanger sequencing
method.
Overall, the present method detected all 250 Sanger
sequencingeveriﬁed gene variations, including single nucle-
otide changes, splice site alterations, and indel mutations,
except for two PKD1 changes residing in the same amplicon
that were ascertained as homozygous by NGS rather than as
heterozygous. In contrast, of the 24 patients with Sanger
sequencingenegative ADPKD, 3 were found to harbor a
pathogenic mutation in PKD1 by the NGS method, subse-
quently conﬁrmed by Sanger sequencing, using different
primers. Except for PKD1 c.3296-2A>T, previously missed
by Sanger sequencing owing a technologist’s error, the two
other discrepancies were due to allele dropout during the LR-
PCR ampliﬁcation step. Allele dropout or reduction to ho-
mozygosity has been well documented, particularly for PKD1,
which is highly polymorphic, and it is likely due to the pres-
ence of an SNP in the primer binding sites in one of the two
alleles, leading to unequal PCR ampliﬁcation of the two het-
erozygous alleles.17,18 This phenomenon is less likely to occur
with NGS because deep sequencing has a signiﬁcantly higher
level of analytical sensitivity of at least 5%32,33 compared
with the Sanger method for detection of mutations in impure
populations of DNAs. Preferential ampliﬁcation of one
allele versus the other can also explain the lower-than-
expected (50%) percentage ALT alleles observed for
approximately 10% of the variants in this study. In addition,
NGS requires only a limited number of primer pairs, as
opposed to >80 pairs with Sanger sequencing, thereby
considerably reducing the chances for mispriming. Never-
theless, in all cases with homozygous mutations, subse-
quent conﬁrmatory sequencing analysis must be performed
to rule out false-positive results.18 Note that the greater
analytical sensitivity achieved by high-depth sequencing
can be particularly suitable for detecting low-abundance
mutations in rare cases of mosaicism. Although false-
positive results have not been seen in this study, we pro-
pose that as a part of a routine clinical workﬂow, alljmd.amjpathol.org - The Journal of Molecular Diagnostics
ADPKD Mutation Analysis by NGSmutations should be conﬁrmed by Sanger sequencing. The
low coverage of the GC-rich exon 1 found in this study for
multiple samples may lead to false-negative results. To
overcome this problem, we suggest that follow-up Sanger
sequencing be used as an alternative method for negative
cases with low coverage (<5).34
One potential limitation of this NGS-based ADPKD geno-
typing approach is that the target enrichment process still re-
quires LR-PCR, and setting up LR-PCR is cumbersome and
complicated, especially when large numbers of samples are
analyzed. Qi et al35 used hybridization-based exon capture as
an approach to ADPKD genotyping. However, although target
enrichment is considerably easier to perform compared with
LR-PCR, this approach is not suitable for distinguishing
PKD1 from the pseudogenes, with a true-positive mutation
detection rate of only 28.6%.35 Low coverage of GC-rich
DNA regions due to the unexpected secondary structure of
the DNA template may also be a limitation and an under-
estimated cause for missed variants, particularly in exon 1 of
PKD1, which is 85% GC rich.17,36 This phenomenon of base
composition bias has been well documented for Illumina
sequencing and is primarily attributed to the enrichment PCR
step during library construction.36 Ampliﬁcation with Accu-
Prime Taq high ﬁdelity enzyme blend at a low primer exten-
sion temperature of 65C has been shown to improve the
overall coverage of higheGC-rich areas.36 In our hands, there
was still very good average read coverage of PKD1 exon 1
(15), allowing for conﬁdent variant calling. However, we
identiﬁed a 156-bp-long region in exon 1 (chr16:2185623-
2185778) in which we observed <5 coverage at one
nucleotide or more and in at least one patient in the cohort.
Unequal and sometimes low coverage in this region indicates
that variants occurring in this region might be missed, sug-
gesting that this amplicon should be added in an excess molar
ratio compared with all other amplicons when pooling to
provide sufﬁcient read depth for a conﬁdent mutation call.17
We note, however, that Sanger sequencing did not detect
any variants in this region in the present cohort despite the high
quality of the Sanger traces (not shown).
Finally, large deletions have been shown to play an
important role in ADPKD in 1% to 3% of cases.37,38
Although the paired-end mapping feature in the genotyp-
ing protocol makes it possible to detect such mutations, it
requires that the deletion is located in the LR-PCR amplicon
(Figure 6). The method will not detect any deletion that is
outside the LR-PCR primer range, requiring the continuing
need for methods such as multiplex ligation-dependent
probe ampliﬁcation.38
In summary, NGS-based ADPKD genetic analysis is a
highly accurate and reliable approach for mutation analysis,
achieving high sensitivity and improved intronic coverage
with a faster turnaround time and lower cost. Optimization
of the workﬂow and the stepwise process quality control
metrics for data analysis will likely become routine for
clinical genetic testing, and NGS would be an appropriate
new standard for clinical genetic testing of ADPKD.The Journal of Molecular Diagnostics - jmd.amjpathol.orgAcknowledgment
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